Advertisement
Canada markets open in 5 hours 44 minutes
  • S&P/TSX

    22,011.72
    +139.76 (+0.64%)
     
  • S&P 500

    5,070.55
    +59.95 (+1.20%)
     
  • DOW

    38,503.69
    +263.71 (+0.69%)
     
  • CAD/USD

    0.7309
    -0.0011 (-0.15%)
     
  • CRUDE OIL

    83.48
    +0.12 (+0.14%)
     
  • Bitcoin CAD

    91,240.67
    +690.94 (+0.76%)
     
  • CMC Crypto 200

    1,419.31
    -4.79 (-0.34%)
     
  • GOLD FUTURES

    2,335.60
    -6.50 (-0.28%)
     
  • RUSSELL 2000

    2,002.64
    +35.17 (+1.79%)
     
  • 10-Yr Bond

    4.5980
    -0.0250 (-0.54%)
     
  • NASDAQ futures

    17,725.50
    +118.75 (+0.67%)
     
  • VOLATILITY

    15.77
    +0.08 (+0.51%)
     
  • FTSE

    8,075.21
    +30.40 (+0.38%)
     
  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     
  • CAD/EUR

    0.6837
    +0.0001 (+0.01%)
     

Analyzing NKTR’s Collaboration with Bristol-Myers Squibb

Analyzing NKTR’s Collaboration with Bristol-Myers Squibb

How Is Nektar Therapeutics Positioned in August? In February, Nektar Therapeutics (NKTR) and Bristol-Myers Squibb (BMY) entered into a collaboration to jointly develop the former’s NKTR-214 in combination with the latter’s Opdivo and Opdivo plus Yervoy and other compounds. The two companies also agreed that Nektar would retain the right to record all global sales of the drug.